153 related articles for article (PubMed ID: 26174900)
1. The role of inflammation in intravenous immune globulin-mediated hemolysis.
Pendergrast J; Willie-Ramharack K; Sampson L; Laroche V; Branch DR
Transfusion; 2015 Jul; 55 Suppl 2():S65-73. PubMed ID: 26174900
[TBL] [Abstract][Full Text] [Related]
2. Possible mechanisms for intravenous immunoglobulin-associated hemolysis: clues obtained from review of clinical case reports.
Padmore R
Transfusion; 2015 Jul; 55 Suppl 2():S59-64. PubMed ID: 26174898
[TBL] [Abstract][Full Text] [Related]
3. Hemolysis upon intravenous immunoglobulin transfusion.
Padmore RF
Transfus Apher Sci; 2012 Feb; 46(1):93-6. PubMed ID: 22169381
[TBL] [Abstract][Full Text] [Related]
4. Acute hemolysis after intravenous immunoglobulin amid host factors of ABO-mismatched bone marrow transplantation, inflammation, and activated mononuclear phagocytes.
Michelis FV; Branch DR; Scovell I; Bloch E; Pendergrast J; Lipton JH; Cserti-Gazdewich CM
Transfusion; 2014 Mar; 54(3):681-90. PubMed ID: 23829192
[TBL] [Abstract][Full Text] [Related]
5. A prospective observational study of the incidence, natural history, and risk factors for intravenous immunoglobulin-mediated hemolysis.
Pendergrast J; Armali C; Callum J; Cserti-Gazdewich C; Jiwajee A; Lieberman L; Lau W; Lin Y; Parmar N; Pavenski K; Riden LS; Shehata N; Willie-Ramharack K; Tomlinson G; Tong TN; Binnington B; Branch DR;
Transfusion; 2021 Apr; 61(4):1053-1063. PubMed ID: 33433931
[TBL] [Abstract][Full Text] [Related]
6. Specifications for anti-A and anti-B in intravenous immunoglobulin: history and rationale.
Thorpe SJ
Transfusion; 2015 Jul; 55 Suppl 2():S80-5. PubMed ID: 26174902
[TBL] [Abstract][Full Text] [Related]
7. Do immune complexes play a role in hemolytic sequelae of intravenous immune globulin?
Zimring JC
Transfusion; 2015 Jul; 55 Suppl 2():S86-9. PubMed ID: 26174903
[TBL] [Abstract][Full Text] [Related]
8. Hemolytic events associated with intravenous immune globulin therapy: a qualitative analysis of 263 cases reported to four manufacturers between 2003 and 2012.
Berg R; Shebl A; Kimber MC; Abraham M; Schreiber GB
Transfusion; 2015 Jul; 55 Suppl 2():S36-46. PubMed ID: 26174896
[TBL] [Abstract][Full Text] [Related]
9. Intravenous immune globulin-related hemolysis: comparing two different methods for case assessment.
Taylor E; Vu D; Legare C; Keene D
Transfusion; 2015 Jul; 55 Suppl 2():S23-7. PubMed ID: 26174894
[TBL] [Abstract][Full Text] [Related]
10. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: a case series analysis.
Daw Z; Padmore R; Neurath D; Cober N; Tokessy M; Desjardins D; Olberg B; Tinmouth A; Giulivi A
Transfusion; 2008 Aug; 48(8):1598-601. PubMed ID: 18466176
[TBL] [Abstract][Full Text] [Related]
11. ABO zygosity, but not secretor or Fc receptor status, is a significant risk factor for IVIG-associated hemolysis.
Branch DR; Hellberg Å; Bruggeman CW; Storry JR; Sakac D; Blacquiere M; Tong TN; Burke-Murphy E; Binnington B; Parmar N; Riden LS; Willie K; Armali C; Aziz J; Lieberman L; Laroche V; Callum J; Lin Y; Shehata N; Pavenski K; Lau W; Hannach B; Kuijpers TW; Olsson ML; Cserti-Gazdewich C; Pendergrast J
Blood; 2018 Feb; 131(7):830-835. PubMed ID: 29305554
[No Abstract] [Full Text] [Related]
12. Intravenous immunoglobulin-related hemolysis in patients treated for Kawasaki disease.
Luban NL; Wong EC; Henrich Lobo R; Pary P; Duke S
Transfusion; 2015 Jul; 55 Suppl 2():S90-4. PubMed ID: 26174904
[TBL] [Abstract][Full Text] [Related]
13. Hemolysis related to intravenous immunoglobulins is dependent on the presence of anti-blood group A and B antibodies and individual susceptibility.
Mielke O; Fontana S; Goranova-Marinova V; Shebl A; Spycher MO; Wymann S; Durn BL; Lawo JP; Hubsch A; Salama A
Transfusion; 2017 Nov; 57(11):2629-2638. PubMed ID: 28840942
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic plasma exchange as a therapeutic modality for the treatment of IVIG complications.
Welsh KJ; Bai Y
J Clin Apher; 2015 Dec; 30(6):371-4. PubMed ID: 26123478
[TBL] [Abstract][Full Text] [Related]
15. Intravenous immune globulin therapy for Stevens-Johnson syndrome/toxic epidermal necrolysis complicated by hemolysis leading to pigment nephropathy and hemodialysis.
Ririe MR; Blaylock RC; Morris SE; Jung JY
J Am Acad Dermatol; 2013 Aug; 69(2):221-5. PubMed ID: 23673282
[TBL] [Abstract][Full Text] [Related]
16. Haemolysis after treatment with intravenous immunoglobulin due to anti-A.
Morgan S; Sorensen P; Vercellotti G; Zantek ND
Transfus Med; 2011 Aug; 21(4):267-70. PubMed ID: 21605202
[TBL] [Abstract][Full Text] [Related]
17. Hemolytic adverse events with immune globulin products: product factors and patient risks.
Scott DE; Epstein JS
Transfusion; 2015 Jul; 55 Suppl 2():S2-5. PubMed ID: 26174893
[No Abstract] [Full Text] [Related]
18. Severe intravenous immunoglobulin-induced hemolysis with pigment nephropathy managed with red cell exchange.
Lasica M; Zantomio D
J Clin Apher; 2016 Oct; 31(5):464-6. PubMed ID: 26297048
[TBL] [Abstract][Full Text] [Related]
19. Intravenous immune globulin affects cytokine production in T lymphocytes and monocytes/macrophages.
Andersson J; Skansén-Saphir U; Sparrelid E; Andersson U
Clin Exp Immunol; 1996 May; 104 Suppl 1():10-20. PubMed ID: 8625537
[TBL] [Abstract][Full Text] [Related]
20. Acute hemolysis in a patient with cytomegalovirus pneumonitis treated with intravenous immunoglobulin (IVIG).
Coghill J; Comeau T; Shea T; Braddy L; Bandarenko N; Afenyi-Annan A; Harvey D
Biol Blood Marrow Transplant; 2006 Jul; 12(7):786-8. PubMed ID: 16785068
[No Abstract] [Full Text] [Related]
[Next] [New Search]
